PMID: 9177496Jan 1, 1997Paper

6-Day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignancies

Journal of Cancer Research and Clinical Oncology
E BrainJ L Misset

Abstract

Ifosfamide is an analogue of cyclophosphamide active in the treatment of numerous tumours. Although its use by continuous infusion seems to be responsible for less toxicity, differences of efficacy and toxicity, observed according to its doses and schedules of administration, still remain debated. The objective of this study was to assess the toxicity of high-dose ifosfamide given by continuous infusion over 6 days and its therapeutic activity in various advanced tumours. Twenty-six patients were treated with 14 g/m2 ifosfamide, an equal dose of MESNA, and routine granulocyte- or granulocyte/macrophage-colony-stimulating factor during the intercycle. Courses were repeated every 3 weeks until disease progression or unacceptable toxicity occurred; 75 cycles were administered. The mean number of cycles per patient was 3 (range 1-11). Extrahaematological toxicity was manageable in most patients, WHO grade II or more neurological (5 patients) and renal (5 patients) toxicities occurring in those heavily pretreated with platinum compounds and presenting peritoneal disease. WHO grade III or more neutropenia occurred in 60% of cycles, while grade III-IV thrombocytopenia and anaemia were observed in 19% of them. Three partial responses (...Continue Reading

References

Dec 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A SuarezF Flamant
Jan 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A D EliasK H Antman
Jan 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K H AntmanH E Grier
Mar 1, 1987·European Journal of Cancer & Clinical Oncology·V H BramwellR Sylvester
Dec 1, 1972·Journal of Pharmaceutical Sciences·L M Allen, P J Creaven
Jul 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A Le CesneJ Genin
Jan 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A V BoddyJ R Idle
Jan 1, 1995·Journal of Cancer Research and Clinical Oncology·H J KeizerF J Cleton
Feb 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B A KamenO M Colvin
Jan 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R RossiH Jürgens

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.